Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bio-Path Holdings, Inc. (NASDAQ: BPTH).

Full DD Report for BPTH

You must become a subscriber to view this report.


Recent News from (NASDAQ: BPTH)

Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2018 Results - Earnings Call Transcript
Bio-Path Holdings, Inc. (BPTH) Q1 2018 Earnings Conference Call April 16, 2018 8:30 PM ET Executives Will O’Connor – Investor Relations Peter Nielsen – President and Chief Executive Officer Anthony Price – Vice President-Finance and Accounting Analy...
Source: SeekingAlpha
Date: May, 16 2018 14:16
Bio-Path Holdings Reports First Quarter 2018 Financial Results
HOUSTON, May 16, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results f...
Source: GlobeNewswire
Date: May, 16 2018 07:00
Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board
HOUSTON, May 10, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Anas...
Source: GlobeNewswire
Date: May, 10 2018 08:00
Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018
HOUSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a liv...
Source: GlobeNewswire
Date: May, 09 2018 08:00
Midday Gainers / Losers (04/19/2018)
Gainers:   ECOM +20% . OPGN +18% . EBIO +17% . EYPT +15% . BPTH +14% . PRAN +13% . CCRC +13% . DXR +11% . ZYNE +11% . DEST +9% . More news on: ChannelAdvisor Corp, OpGen, Eleven Biotherapeutics, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 19 2018 12:40
Premarket Gainers as of 9:05 am (04/19/2018)
BPTH +20%  after presentation  of prexigebersen data. More news on: Bio-Path Holdings, Inc., Sientra, W.W. Grainger, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 19 2018 09:09
Bio-Path +38.6% after presentatiom of prexigebersen data
Bio-Path Holdings (NASDAQ: BPTH ) is up 38.6% postmarket after presenting pre-clinical data from studies supporting prexigebersen in treating solid tumors in gynecologic malignancies at the annual meeting of the American Association for Cancer Research. More news on: Bio-Path Holdings,...
Source: SeekingAlpha
Date: April, 18 2018 19:29
Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that data from pre-cl...
Source: GlobeNewswire
Date: April, 18 2018 16:01
Wired News - EMA Completed Validation of MAA for Aradigm's Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Stock Monitor: Bio-Path Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Aradigm Corp. (NASDAQ: ARDM ). If you want access to this report all you need to do is sign up now by clicking the foll...
Source: ACCESSWIRE IA
Date: April, 09 2018 07:20
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 06 2018 07:14

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-171.411.47421.541.4120,393
2018-08-161.491.4721.531.450111,745
2018-08-151.461.501.501.420110,169
2018-08-141.471.521.52991.4021,739
2018-08-131.481.431.5291.4134,519

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-172,1028,12725.8644Cover
2018-08-166302,86022.0280Cover
2018-08-154416,9936.3063Cover
2018-08-141,2003,17837.7596Short
2018-08-133002,84910.5300Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BPTH.


About Bio-Path Holdings, Inc. (NASDAQ: BPTH)

Logo for Bio-Path Holdings, Inc. (NASDAQ: BPTH)

Bio Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Currently in Phase human trial.

 

Contact Information

 

 

Current Management

  • Peter Nielsen / CEO, CFO, COO
  • Peter Nielsen / Chairman
  • Michael J. Garrison /
  • Gillian IversRead /
  • Douglas P. Morris /

Current Share Structure

  • Market Cap: $19,518,575 - 05/14/2018
  • Issue and Outstanding: 11,340,756 - 03/22/2018

 


Recent Filings from (NASDAQ: BPTH)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 03 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018

 

 


Daily Technical Chart for (NASDAQ: BPTH)

Daily Technical Chart for (NASDAQ: BPTH)


Stay tuned for daily updates and more on (NASDAQ: BPTH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BPTH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPTH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BPTH and does not buy, sell, or trade any shares of BPTH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/